Kyntra Bio (NASDAQ:KYNB – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of recent recommendations for Kyntra Bio and Celularity, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 4 | 0 | 2.50 |
| Celularity | 1 | 0 | 0 | 0 | 1.00 |
Kyntra Bio presently has a consensus target price of $37.25, suggesting a potential upside of 432.14%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Kyntra Bio is more favorable than Celularity.
Risk and Volatility
Insider and Institutional Ownership
72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Kyntra Bio and Celularity”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyntra Bio | $6.44 million | 4.40 | $183.45 million | $45.30 | 0.15 |
| Celularity | $26.55 million | 1.44 | -$91.72 million | ($3.33) | -0.40 |
Kyntra Bio has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Kyntra Bio and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
| Celularity | -345.45% | N/A | -77.94% |
Summary
Kyntra Bio beats Celularity on 11 of the 13 factors compared between the two stocks.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
